First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: Do we need aggressive treatment?

Oncology

Volumn 77, Issue 5, 2009, Pages 318-327

  Debled, Marc ^a   Madranges, Nicolas ^a   Trainaud, Alexandra ^b   Floquet, Anne ^a   Donamaria, Catherine ^b   Brouste, Véronique ^a   Durand, Michel ^a   Mauriac, Louis ^a  

^a INSTITUT BERGONIÉ   (France)

^b Department of Pharmacy ^*

Author keywords

Capecitabine; First line chemotherapy; Metastatic breast cancer; Monotherapy; Oral administration; Quality of life

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; HORMONE RECEPTOR; MITOMYCIN C; NAVELBINE; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE DURATION; DRUG FATALITY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PANCYTOPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE;

EID: 70450208728     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000260904     Document Type: Article

References (29)

1. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998; 339: 974-984.
2. von Minckwitz G, The Breast Commission of the German Gynaecological Oncology Working Group (AGO): Evidence-based treatment of metastatic breast cancer - 2006 recommendations by the AGO Breast Commission. Eur J Cancer 2006; 42: 2897-2908.
3. Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005; 2: CD003372.
4. Wilcken N, Hornbuckle J, Ghersi D: Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003; 2:CD002747.
5. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Kostler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H: Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007; 18: 215-225. (Pubitemid 46323085)
6. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 7: 485-493.
7. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759-1768.
8. O'Shaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as firstline therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247-1254.
9. Reichardt P, von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Luck HJ: Multicenter phase II study of oral capecitabine (Xeloda® ) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14: 1227-1233.
10. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere JF, Montestruc F, Mouri Z, Namer M: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthra cyclineand taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40: 536-542.
11. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
12. Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V: Lower dose capecitabine has a more favourable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16: 1289-1296.
13. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J: Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 1999; 56: 67-78.
14. Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 2155-2161.
15. Soto C, Torrecillas L, Reyes S, Ramirez M, Perez L, Cervantes G, Gonzalez F, Tellez E, Cortes P, Benitez H: Capecitabine (X) and taxanes in patients (pts) with anthracyclinepretreated metastatic breast cancer (MBC): sequential versus combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 2006; 24(18s):570.
16. Stockler M, Sourjina T, Grimison P, Gebski V, Byrne M, Harvey V, Francis P, Nowak AK, Van Hazel G, Forbes J, ANZ Breast Cancer Trials Group: A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2007; 25: 1031.
17. Yap YS, Kendall A, Walsh G, Banerji U, Johnston SR, Smith IE, O'Brien M: Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer - how low can you go? Breast 2007; 16: 420-424.
18. Coates AS, Stockler M, Wilcken N: Controversies in metastatic breast cancer: optimal duration of chemotherapy. ASCO Educational Handbook 2003; 119-121.
19. Payne SA: A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992; 35: 1505-1509.
20. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
21. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-358.
22. Gornaœ M, Szczylik C: Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process? Eur J Cancer Care (Engl) 2009 Jul 20 (Epub ahead of print).
23. Tosello C, Segalla JGM, Ribeiro R, Tessaro S, Cabral S, Frank F, Perdicaris M, de Paula U, Moura G, Rego C: Improvements in quality of life (QoL) associated with capecitabine treatment for metastatic breast cancer (MBC) in Brazil: updated results from a large cohort of 1683 patients, including analysis as a function of ECOG PS (abstract 5073). Breast Cancer Res Treat 2006; 100(suppl 1):S278.
24. Llombart A, Nag S, Calderillo-Ruiz G, Rolski J, Pluzanska A, Simms L, Look K, Gill J, Melemed A, O'Shaughnessy J: Phase III study of gemcitabine (G) plus paclitaxel (T) versus T in patients with metastatic breast cancer (MBC) - post-study chemotherapy (PSC) trend analysis (abstract 568). Eur J Cancer Suppl 2008; 6: 217.
25. Jassem J, Pieñkowski T, Płuzañska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C, Central & Eastern Europe and Israel Paclitaxel Breast Cancer Study Group: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as firstline therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707-1715.
26. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000; 18: 724-733.
27. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17: 2355-2364.
28. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P, TAX 306 Study Group: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as firstline chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21: 968-975.
29. Miles D, Vukelja S, Moiseyenko V, Cervantes G, Mauriac L, Van Hazel G, Liu WY, Ayoub JP, O'Shaughnessy JA: Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin Breast Cancer 2004; 5: 273-278.